论文部分内容阅读
尿激酶原(单链尿激酶型纤维蛋白溶酶原活化剂)在体外和各类动物中均显示出其对纤维蛋白的专一性。本探索性研究是测定糖化尿激酶原的不同治疗方案对纤维蛋白的专一性及溶栓的有效性。方法:从变性的肾脏细胞TCL-598的条件培养液中提纯的人类尿激酶原。供使用的药物置于小瓶中,含375mg冷冻干燥的尿激酶原,贮藏在4℃中,用前只需在10cc水中即溶解。用等率输注泵将适当药量在1小时内滴完。受试者年龄均<75岁,典型胸痛至少持续30min且S-T段肢Ⅲ导联抬高至少2mm的心肌梗塞者,均无使用心导管或溶栓治疗的禁忌征象。结果:54例病人均用10,000U的肝素抗凝治疗。按治疗方案的不同分为3组。组Ⅰ14例病人先弹丸注射7.5mg尿激酶原,接着滴注40.5mg(总量48mg)在1小时内滴完,即观察到其中7例(50％)的梗
Pro-urokinase (single-chain urokinase-type plasminogen activator) shows its specificity for fibrin both in vitro and in various animal types. This exploratory study is the determination of the specificity of fibrin and the effectiveness of different thrombolytic agents for the treatment of glycated prourokinase. Methods: Human urokinase purified from conditioned medium from denatured kidney cells TCL-598. The drug to be used is placed in a vial containing 375 mg of lyophilized pro-urokinase stored at 4 ° C and dissolved in 10 cc of water just prior to use. Equal rate infusion pump the appropriate dose drops within 1 hour. None of the subjects underwent cardiac catheterization or thrombolytic therapy for signs of cardiac catheterization or thrombolysis in patients with myocardial infarction <75 years of age, typical chest pain lasting at least 30 minutes, and elevation of at least 2 mm in the S-T segment. Results: All 54 patients were treated with 10,000 U heparin anticoagulant. According to the different treatment programs are divided into 3 groups. Group I14 patients were injected with prolactin 7.5 mg prolactin followed by instillation of 40.5 mg (48 mg total) within 1 hour, of which 7 (50%) were observed